Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
This company is serious about maintaining its leadership.
Both of these businesses are finding traction in a pair of major markets.
Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects....
This mid-cap biopharma may one day be a titan of the industry.
There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...
These stocks are both experts in their respective fields.
These pharmaceutical companies are top-notch dividend growth stocks for the future.
This is a stock you shouldn't hesitate to buy on the dip.
The anti-obesity medication stock is way up, and there could be more fuel in the tank.